Organoid Models for Precision Cancer Immunotherapy
Cancer immunotherapy is exploited for the treatment of disease by modulating the immune system. Since the conventional in vivo animal and 2D in vitro models insufficiently recapitulate the complex tumor immune microenvironment (TIME) of the original tumor. In addition, due to the involvement of the...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.770465/full |
| _version_ | 1818755580657926144 |
|---|---|
| author | Cai-Ping Sun Huan-Rong Lan Xing-Liang Fang Xiao-Yun Yang Ke-Tao Jin |
| author_facet | Cai-Ping Sun Huan-Rong Lan Xing-Liang Fang Xiao-Yun Yang Ke-Tao Jin |
| author_sort | Cai-Ping Sun |
| collection | DOAJ |
| description | Cancer immunotherapy is exploited for the treatment of disease by modulating the immune system. Since the conventional in vivo animal and 2D in vitro models insufficiently recapitulate the complex tumor immune microenvironment (TIME) of the original tumor. In addition, due to the involvement of the immune system in cancer immunotherapy, more physiomimetic cancer models, such as patient-derived organoids (PDOs), are required to evaluate the efficacy of immunotherapy agents. On the other hand, the dynamic interactions between the neoplastic cells and non-neoplastic host components in the TIME can promote carcinogenesis, tumor metastasis, cancer progression, and drug resistance of cancer cells. Indeed, tumor organoid models can properly recapitulate the TIME by preserving endogenous stromal components including various immune cells, or by adding exogenous immune cells, cancer-associated fibroblasts (CAFs), vasculature, and other components. Therefore, organoid culture platforms could model immunotherapy responses and facilitate the immunotherapy preclinical testing. Here, we discuss the various organoid culture approaches for the modeling of TIME and the applications of complex tumor organoids in testing cancer immunotherapeutics and personalized cancer immunotherapy. |
| first_indexed | 2024-12-18T05:41:25Z |
| format | Article |
| id | doaj.art-aeb895aad2f741a5b768b9dd810a5299 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-18T05:41:25Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-aeb895aad2f741a5b768b9dd810a52992022-12-21T21:19:10ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-04-011310.3389/fimmu.2022.770465770465Organoid Models for Precision Cancer ImmunotherapyCai-Ping Sun0Huan-Rong Lan1Xing-Liang Fang2Xiao-Yun Yang3Ke-Tao Jin4Department of Medical Oncology, Shaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, ChinaDepartment of Breast and Thyroid Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, ChinaDepartment of Hepatobiliary Surgery, Affiliated Hospital of Shaoxing University College of Medicine (Shaoxing Municipal Hospital), Shaoxing, ChinaDepartment of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, ChinaDepartment of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, ChinaCancer immunotherapy is exploited for the treatment of disease by modulating the immune system. Since the conventional in vivo animal and 2D in vitro models insufficiently recapitulate the complex tumor immune microenvironment (TIME) of the original tumor. In addition, due to the involvement of the immune system in cancer immunotherapy, more physiomimetic cancer models, such as patient-derived organoids (PDOs), are required to evaluate the efficacy of immunotherapy agents. On the other hand, the dynamic interactions between the neoplastic cells and non-neoplastic host components in the TIME can promote carcinogenesis, tumor metastasis, cancer progression, and drug resistance of cancer cells. Indeed, tumor organoid models can properly recapitulate the TIME by preserving endogenous stromal components including various immune cells, or by adding exogenous immune cells, cancer-associated fibroblasts (CAFs), vasculature, and other components. Therefore, organoid culture platforms could model immunotherapy responses and facilitate the immunotherapy preclinical testing. Here, we discuss the various organoid culture approaches for the modeling of TIME and the applications of complex tumor organoids in testing cancer immunotherapeutics and personalized cancer immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2022.770465/fullcancerimmunotherapyorganoidprecision medicinetumor microenvironment |
| spellingShingle | Cai-Ping Sun Huan-Rong Lan Xing-Liang Fang Xiao-Yun Yang Ke-Tao Jin Organoid Models for Precision Cancer Immunotherapy Frontiers in Immunology cancer immunotherapy organoid precision medicine tumor microenvironment |
| title | Organoid Models for Precision Cancer Immunotherapy |
| title_full | Organoid Models for Precision Cancer Immunotherapy |
| title_fullStr | Organoid Models for Precision Cancer Immunotherapy |
| title_full_unstemmed | Organoid Models for Precision Cancer Immunotherapy |
| title_short | Organoid Models for Precision Cancer Immunotherapy |
| title_sort | organoid models for precision cancer immunotherapy |
| topic | cancer immunotherapy organoid precision medicine tumor microenvironment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.770465/full |
| work_keys_str_mv | AT caipingsun organoidmodelsforprecisioncancerimmunotherapy AT huanronglan organoidmodelsforprecisioncancerimmunotherapy AT xingliangfang organoidmodelsforprecisioncancerimmunotherapy AT xiaoyunyang organoidmodelsforprecisioncancerimmunotherapy AT ketaojin organoidmodelsforprecisioncancerimmunotherapy |